	US 12,233,094 B2
	Interaction of fibroblasts and immune cells for activation and uses thereof
Pete O'Heeron, Houston, TX (US); and Thomas Ichim, San Diego, CA (US)
Assigned to Spinalcyte, LLC, Houston, TX (US)
Appl. No. 16/765,060
Filed by SPINALCYTE LLC, Houston, TX (US)
PCT Filed Nov. 29, 2018, PCT No. PCT/US2018/063001 § 371(c)(1), (2) Date May 18, 2020, PCT Pub. No. WO2019/108756, PCT Pub. Date Jun. 6, 2019.
Claims priority of provisional application 62/591,858, filed on Nov. 29, 2017.
Prior Publication US 2021/0393700 A1, Dec. 23, 2021
Int. Cl. A61K 35/33 (2015.01); A61K 35/17 (2015.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61P 21/00 (2006.01); A61P 37/06 (2006.01); C12N 5/0783 (2010.01); C12N 5/0786 (2010.01)

CPC A61K 35/33 (2013.01) [A61K 35/17 (2013.01); A61K 38/1825 (2013.01); A61K 38/1841 (2013.01); A61K 38/1866 (2013.01); A61K 38/20 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01); A61P 37/06 (2018.01); C12N 5/0637 (2013.01); C12N 5/0645 (2013.01)]

13 Claims

1. A method for generating and using a population of regulatory T cells for cell therapy, comprising the steps of:

exposing a composition comprising activated fibroblast cells and transforming growth factor (TGF)-beta to cluster of differentiation (CD) 25⁺ regulatory T cells and

administering the regulatory T cells to an individual with an effective amount of one or more immunomodulatory agents.